Benefit-Risk of Ponatinib Vs. Bosutinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Failed Two Prior Tyrosine Kinase Inhibitors (TKIs): An Indirect Comparison

被引：2
|
作者：
Levy, Moshe Yair [1 ]
McGarry, Lisa J. [2 ]
Huang, Hui [2 ]
Lustgarten, Stephanie [2 ]
Nieset, Christopher [2 ]
Haluska, Frank G. [2 ]
机构：
[1] Baylor Univ, Med Ctr, Dallas, TX USA
[2] ARIAD Pharmaceut Inc, Cambridge, MA 02139 USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
10.1182/blood.V124.21.3154.3154
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Outcome after Discontinuation of Second Generation Tyrosine Kinase Inhibitors (TKIs) Used As Frontline Therapy for Patients (pts) with Chronic Phase (CP) Chronic Myeloid Leukemia (CML)
    Abdelall, Waleed
    Kantarjian, Hagop M.
    Devendra, K. C.
    Akosile, Mary
    Borthakur, Gautam
    Verstovsek, Srdan
    Daver, Naval
    Pemmaraju, Naveen
    Naqvi, Kiran
    Garcia-Manero, Guillermo
    Thompson, Philip A.
    Ferrajoli, Alessandra
    Ravandi, Farhad
    Konopleva, Marina
    DiNardo, Courtney D.
    Jabbour, Elias J.
    Cortes, Jorge E.
    BLOOD, 2017, 130
  • [32] A MODEL-BASED ASSESSMENT OF THE BENEFITS AND RISKS OF PONATINIB VERSUS BOSUTINIB IN THIRD-LINE TREATMENT OF CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML)
    Cartier, S.
    Parthan, A.
    McGarry, L.
    Weinstein, M.
    HAEMATOLOGICA, 2015, 100 : 149 - 150
  • [33] A multicenter, randomized phase III study of asciminib (ABL001) versus bosutinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with ≥2 tyrosine kinase inhibitors (TKIs).
    Mauro, Michael J.
    Hochhaus, Andreas
    Boquimpani, Carla
    Minami, Yosuke
    Allepuz, Alex
    Polydoros, Fotis
    Bedoucha, Veronique
    Aimone, Paola
    Rea, Delphine
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [34] Matching-Adjusted Indirect Comparisons (MAICs) of Asciminib vs Other Tyrosine Kinase Inhibitors (TKIs) in Third- or Later-Line Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
    Atallah, Ehab
    Jadhav, Kejal
    Kangappaden, Teresa
    Damon, Andrea
    Samjoo, Imtiaz
    Wei, David
    Bhattacharyya, Devarshi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S337 - S337
  • [35] Omacetaxine mepesuccinate in chronic-phase chronic myeloid leukemia (CML) in patients resistant, intolerant, or both to two or more tyrosine-kinase inhibitors (TKIs)
    Akard, Luke Paul
    Kantarjian, Hagop
    Nicolini, Franck E.
    Wetzler, Meir
    Howard, Jeffrey
    Baccarani, Lipton Michele
    Craig, Adam
    Nanda, Nisha
    Brown, Peter D.
    Cortes, Jorge E.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [36] Responses With Asciminib Continue to Deepen Over Time in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase III ASCEMBL Study
    Mauro, Michael
    Hochhaus, Andreas
    Hughes, Timothy
    Rea, Delphine
    Boquimpani, Carla
    Minami, Yosuke
    Apperley, Jane
    Garcia-Gutierrez, Valentin
    Kapoor, Shruti
    Espurz, Noemi
    Dhamal, Vishal
    Cortes, Jorge
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S340 - S340
  • [37] Achieving Early Landmark Response Is Predictive of Outcomes in Heavily Pretreated Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib
    Mueller, Martin C.
    Baccarani, Michele
    Deininger, Michael W.
    Guilhot, Francois
    Hochhaus, Andreas
    Hughes, Timothy P.
    Shah, Neil P.
    Talpaz, Moshe
    Lustgarten, Stephanie
    Rivera, Victor M.
    Clackson, Tim
    Haluska, Frank G.
    Cortes, Jorge E.
    BLOOD, 2014, 124 (21)
  • [38] Correction: Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials
    Jabbour, Elias
    Apperley, Jane
    Cortes, Jorge
    Rea, Delphine
    Deininger, Michael
    Abruzzese, Elisabetta
    Chuah, Charles
    Deangelo, Daniel J.
    Hochhaus, Andreas
    Lipton, Jeffrey H.
    Mauro, Michael
    Nicolini, Franck
    Pinilla-Ibarz, Javier
    Rosti, Gianantonio
    Rousselot, Philippe
    Shah, Neil P.
    Talpaz, Moshe
    Vorog, Alexander
    Ren, Xiaowei
    Kantarjian, Hagop
    LEUKEMIA, 2024, 38 (10) : 2291 - 2291
  • [39] Thrombogenesis Mechanisms of High Doses of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) Compared to Tyrosine Kinase Inhibitors
    Aguila, Sonia
    Cuenca, Ernesto J.
    Lys, Maria Jose
    Garcia-Hernandez, Carmen
    Jose Fernandez, Maria
    Noya, Maria
    Garcia Gutierrez, Valentin
    Palomera, Luis
    Senin, Alicia
    Perez Lopez, Raul
    Perez-Encinas, Manuel
    Angona, Anna
    Puerta, Jose M.
    Vallansot, Rolando
    Conesa, Venancio
    Hernandez Boluda, Juan Carlos
    Rosell, Ana
    Cortes, Montse
    Orti, Guillermo
    Xicoy, Blanca
    Carreno, Gonzalo
    Mora Castera, Elvira
    Giraldo, Pilar
    Luisa Lozano, Maria
    Felipe Casado, Luis
    Ferrer Marin, Francisca
    BLOOD, 2022, 140 : 6730 - 6732
  • [40] Long-Term Follow-up of a Phase 1 Study of Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)
    Talpaz, Moshe
    Cortes, Jorge E.
    Kantarjian, Hagop
    Shah, Neil P.
    Bixby, Dale
    Flinn, Ian
    O'Hare, Thomas
    Hu, Simin
    Rivera, Victor M.
    Clackson, Tim
    Turner, Christopher D.
    Haluska, Frank G.
    Druker, Brian J.
    Deininger, Michael W.
    Mauro, Michael J.
    BLOOD, 2014, 124 (21)
12345